Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial

INTRODUCTION: Randomized trials of new agents for HIV pre‐exposure prophylaxis (PrEP) compare against emtricitabine and tenofovir disoproxil fumarate (F/TDF), without a placebo group. We used the well‐characterized adherence‐efficacy relationship for F/TDF to back‐calculate the (non‐PrEP) counterfac...

Descripción completa

Detalles Bibliográficos
Autores principales: Glidden, David V, Das, Moupali, Dunn, David T, Ebrahimi, Ramin, Zhao, Yongwu, Stirrup, Oliver T, Baeten, Jared M, Anderson, Peter L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140182/
https://www.ncbi.nlm.nih.gov/pubmed/34021709
http://dx.doi.org/10.1002/jia2.25744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140182/
https://www.ncbi.nlm.nih.gov/pubmed/34021709
http://dx.doi.org/10.1002/jia2.25744

Ejemplares similares